Despite the enormous potential of conditionally replicating adenoviruses (CRAs), the time-consuming and laborious methods required to construct CRAs have hampered both the development of CRAs that can specifically target tumors with multiple factors (m-CRA) and the efficient analysis of diverse candidate CRAs. Here, we present a novel method for efficiently constructing diverse m-CRAs. Elements involving viral replication, therapeutic genes, and adenoviral backbones were separately introduced into three plasmids of P1, P2, and P3, respectively, which comprised different antibiotic resistant genes, different ori, and a single loxP (H) sequence. Independently constructed plasmids were combined at 100% accuracy by transformation with originally prepared Cre and specific antibiotics in specific Escherichia coli; transfection of the resulting P1+2+3 plasmids into 293 cells efficiently generated m-CRAs. Moreover, the simultaneous generation of diverse m-CRAs was achieved at 100% accuracy by handling diverse types of P1+2 and P3. Alternatively, co-transfection of P1+3 and P2 plasmids into Cre-expressing 293 cells directly generated m-CRA with therapeutic genes. Thus, our three-plasmid system, which allows unrestricted construction and efficient fusion of individual elements, should expedite the process of generating, modifying, and testing diverse m-CRAs for the development of the ideal m-CRA for tumor therapy. Keywords: conditionally replicating adenovirus; cancer; tumor-specific; Cre/lox recombination Introduction One of the major obstacles to cancer gene therapy is inefficient and nonspecific gene delivery to cancer cells, leading to unsatisfactory outcomes in clinical trials due to recurrence from nontransduced tumor cells, even though some of the effective strategies, such as suicide gene therapy, 1,2 immunological gene therapy, 3, 4 and their combinations 5 may treat nontransduced tumor cells to some degree and partially circumvent this problem. Conditionally replicating adenoviruses (CRAs), which selectively replicate in tumor cells, but not in normal cells, have the potential to circumvent this problem and to achieve tumor-specific gene delivery. 6, 7 Moreover, CRA itself may be an attractive tool for innovative cancer therapy because selectively propagated adenovirus (Ad) induces the lysis of tumor cells. While various CRAs have been reported to date, the majority of them may be classified into two groups. 8 One is CRA that expresses E1 in a tumor-specific manner by the replacement of a native E1 promoter with various tumor-specific promoters. [9] [10] [11] [12] The other is CRA with a partial deletion of the E1 gene; the representatives are the mutant (mt) type of Ad lacking a p53-binding protein that is encoded by E1B55kD (ONYX-015), 13 and the mt Ad lacking an Rbbinding site of E1A (D24). 14, 15 In the case of infection with the wild type of Ad, E1B55kD inhibits the p53-induced apoptosis of the host cell and enables Ad to continuously replicate in cells. 13, 16 In addition, the interaction of adenoviral E1A with cellular Rb leads to the release of E2F transcription factor, which induces S-phase transition of the host cell in order to facilitate viral replication. 16 Based on these theories, neither mt ONYX-015 nor D24 may efficiently replicate in normal cells with intact Rb and p53, whereas both CRAs may actively replicate in the majority of tumor cells, disrupting the Rb-E2F pathway and/or p53 function.
Introduction
One of the major obstacles to cancer gene therapy is inefficient and nonspecific gene delivery to cancer cells, leading to unsatisfactory outcomes in clinical trials due to recurrence from nontransduced tumor cells, even though some of the effective strategies, such as suicide gene therapy, 1,2 immunological gene therapy, 3, 4 and their combinations 5 may treat nontransduced tumor cells to some degree and partially circumvent this problem. Conditionally replicating adenoviruses (CRAs), which selectively replicate in tumor cells, but not in normal cells, have the potential to circumvent this problem and to achieve tumor-specific gene delivery. 6, 7 Moreover, CRA itself may be an attractive tool for innovative cancer therapy because selectively propagated adenovirus (Ad) induces the lysis of tumor cells. While various CRAs have been reported to date, the majority of them may be classified into two groups. 8 One is CRA that expresses E1 in a tumor-specific manner by the replacement of a native E1 promoter with various tumor-specific promoters. [9] [10] [11] [12] The other is CRA with a partial deletion of the E1 gene; the representatives are the mutant (mt) type of Ad lacking a p53-binding protein that is encoded by E1B55kD (ONYX-015), 13 and the mt Ad lacking an Rbbinding site of E1A (D24). 14, 15 In the case of infection with the wild type of Ad, E1B55kD inhibits the p53-induced apoptosis of the host cell and enables Ad to continuously replicate in cells. 13, 16 In addition, the interaction of adenoviral E1A with cellular Rb leads to the release of E2F transcription factor, which induces S-phase transition of the host cell in order to facilitate viral replication. 16 Based on these theories, neither mt ONYX-015 nor D24 may efficiently replicate in normal cells with intact Rb and p53, whereas both CRAs may actively replicate in the majority of tumor cells, disrupting the Rb-E2F pathway and/or p53 function.
However, a perfect CRA, which replicates efficiently in cancer cells but is completely attenuated in normal cells, has not yet been established in reality. Especially, the crucial problem of current CRAs is the insufficient or incomplete cancer specificity; that is, these CRAs do replicate in and cause some cytopathic effects, while greatly attenuated, in normal cells. [17] [18] [19] Recent studies suggested that CRAs with two or three tumor specific factors enhanced their tumor specificity: mt E1A and mt E1B, 20 two tumor-specific promoters, 21 or a tumorspecific promoter and mt E1A. 12, 22 In this regard, a promising approach to circumvent this obstacle might be combining and introducing multiple (more than three) tumor-specific factors into a single CRA. However, extensive and comparative studies on CRAs that are regulated with multiple tumor-specific factors (m-CRAs) are currently hampered by the lack of standardized methods to efficiently construct m-CRAs in contrast to well-established methods for efficiently constructing E1-deleted replication-incompetent Ad vectors. [23] [24] [25] It remains time-consuming and laborious to construct diverse m-CRAs using current methods; the requirement of additional modification steps hampers efficient production of diverse m-CRAs in large numbers by the same protocol. In addition, although functions of individual viral proteins have been largely elucidated, 16 the controversy over p53-dependent replication of the most representative CRA, ONYX-015, 13, 17, 18 suggests the necessity of extensive biological and systematic virological analyses of a large number of diverse m-CRAs in practice.
Here, we develop a novel method for the efficient construction of m-CRAs; this system simplifies and expedites the generation and modification of m-CRAs.
Results

Constitution of m-CRAs
One of the characteristic features of our method is the independent and unrestricted construction of three different regulatory elements in m-CRA, involving viral replication, therapeutic genes, and Ad backbones. To this end, these elements were separately introduced into three plasmids (Figure 1a ). Replication-controllable plasmid P1 consists of wt or mt E1A and E1B sequences. Therapeutic gene-cloning plasmid P2 characteristically contains the tetracycline resistance gene (tet r ) and R6Kg ori, which render this plasmid selectively amplified in only a specific type of Escherichia coli (E. coli) expressing the pir gene. 26 The Ad backbone plasmid P3 was described previously. 23 Potentially, more than seven tumor-specific factors can be introduced into the m-CRA (Figure 1a) .
The use of different antibiotic resistance genes in all three plasmids, characteristically specific ori in P2 and unique I-CeuI and PI-SceI restriction sites in P1 and P3, enable the independent and unrestricted construction of three plasmids, and, subsequently, the feasible and rapid fusion of these three plasmids to generate a single CRA plasmid without using a regular ligation procedure. This is accomplished in the following manner (Figure 1b) . Four variants of P1 vector with different combinations of wt or mt of E1A and E1B can be chosen at present. After the therapeutic gene and the promoters of interest were inserted into the multiple-cloning sites in P1 and P2, these two vectors were mixed and incubated with Cre aliquot. DH5a E. coli was transformed using all of the mixtures, and then grown on LB plates containing 5 mg/ml tetracycline. As P1 or P2 has either the kanamycin resistance gene (kan r ) or R6Kg ori but not both, only the DH5a clone containing successfully recombined plasmid P1+2 will grow and form a colony on the LB plates containing tetracycline. P3 is digested with I-CeuI and PI-SceI, and ligated with I-CeuI/PI-SceIdigested P1+2, yielding a single P1+2+3 plasmid. Finally, this P1+2+3 plasmid, that is, Ad vector plasmid containing a replication-regulatory element and therapeutic gene, is linearized by PacI, and transfected into 293 cells, as described previously. 5, 23 Miniprep DNA can be used in all of the procedures, including the transfection; this feature increases the rapidity of this method and allows the handling of numerous samples simultaneously.
Preparation of Cre recombinase
Commercial Cre recombinase is so expensive that it prohibits the manipulation of a large number of samples in the present system. To circumvent this obstacle, we developed a feasible and inexpensive way to obtain a solution containing highly active Cre recombinase as follows. HepG2 cells, which demonstrated the highest level of transgene expression and the highest adenoviral gene transduction efficiency (data shown elsewhere), were infected with Ad.CA-Cre (Ad expressing Cre under the strongest CA promoter, which was kindly donated by I Saito) at an MOI of 30 for 2 days, and were then harvested and lysed in 200 ml buffer containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, and 10% glycerol by three rounds of freeze-thawing. The supernatants after centrifugation were collected and stored in aliquots at À801C until use.
We compared the activity of our Cre aliquot with commercial products using two plasmids which had a single loxP sequence. At 1 day after the transformation of E. coli with our Cre aliquot and growth on 10 cm LB plates, several hundred colonies appeared and all colonies were correctly recombined to form a single plasmid (data not shown). Unexpectedly, two of the three commercial lots from two representative companies did not work well (no and one colony). Thus, the Cre activity in our aliquot was sufficiently high for reliable Cre/lox recombination in E. coli; we used this Cre aliquot for the following m-CRA construction (supernatant from one 10 cm dish allowed 200 samples of reaction).
Construction of CEA-responsive m-CRAs
To test the efficiency and the feasibility of this system, we generated carcinoembryonic antigen (CEA) responsive m-CRAs as an example, in which either wt or mt E1A was expressed under the transcriptional control of the CEA promoter (CEApr). Both types of m-CRA have mt E1B (E1BD55kD) downstream from the cytomegalovirus immediate-early gene enhancer/promoter (CMVpr). As a P2 plasmid, pUni/CMVpr-EGFP was used.
After the recombination of P1 and P2 with Cre aliquot, followed by the transformation of DH5a and growth, 10-50 colonies per 10 cm LB-tetracycline plate appeared. Notably, restriction enzyme analyses demonstrated that all of the clones contained the correctly recombined plasmid (pCEApr-E1A-CMVpr-E1BD55kD/CMVpr-EGFP or pCEApr-E1AD24-CMVpr-E1BD55kD/CMVpr-EGFP; we term each P1+2 plasmid as 'pP1-component/ P2-component') ( Figure 2a ). The somewhat lower titer here than that shown in an earlier section was due to tetracycline selection, but not due to Cre/lox recombination efficiency, according to our preliminary studies (data not shown), whereas the result of 100% accuracy in 10-50
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Elements involving viral replication and the therapeutic gene were transferred from P1+2 to P3 (pAd.HM4) to generate P1+2+3 (pAd.HM4-CEApr-E1A-CMVprE1BD55kD/CMVpr-EGFP or pAd.HM4-CEApr-E1AD24-CMVpr-E1BD55kD/CMVpr-EGFP; we term each P1+2+3 adenoviral plasmid as 'pAd.P3-component-P1-component/P2-component'). The accuracy of such unique ICeuI/PI-SceI-based ligation was almost 100% (Figure 2b ), in accordance with the previous results. 23 Over 10 plaques appeared on 6 cm dishes 12 days after the transfection of PacI-digested P1+2+3 into 293 cells. Notably, all of the plaques were EGFP-positive under fluorescent microscopy ( Figure 2c ). Accordingly, the PCR analyses of the DNA extracted from these m-CRAs verified that all of them were correct CEA-responsive m-CRA (CRA.CEApr-E1A-CMVpr-E1BD55kD/CMVpr-EGFP or CRA.CEApr-E1AD24-CMVpr-E1BD55kD/CMVpr-EGFP; we term each m-CRA as 'CRA.P1-component/ P2-component') ( Figure 2d ).
Simultaneous construction of diverse types of m-CRAs
It would further facilitate extensive analyses of m-CRAs if numerous and diverse types of m-CRAs could be constructed at one time. To investigate this possibility, we first investigated whether initially constructed P1+3, that is, Ad backbone plasmid with a replication-regulatory An efficient construction of m-CRAs S Nagano et al element, might be recombined with therapeutic genecloning vector P2 in the same way as the recombination of P1 and P2 (Figure 3a) . P1+3 (pAd.HM4-CEApr-E1A-CMVpr-E1BD55kD) was constructed by transferring replication-regulatory elements from P1 (pCEApr-E1A-CMVpr-E1BD55kD) to P3 (pAd.HM4) with I-CeuI/ PI-SceI-based ligation. After incubating P1+3 (pAd. HM4-CEApr-E1A-CMVpr-E1BD55kD) and P2 (pUni/ CMVpr-EGFP) with Cre aliquot, DH5a was transformed with all of the mixtures and grew on LB plates with tetracycline. After 1 day, about 30 colonies appeared on a 10 cm dish, and all of them contained correctly recombined P1+2+3 plasmid (pAd.HM4-CEApr-E1A-CMVprE1BD55kD/CMVpr-EGFP) (Figure 3b ). Thus, both the efficiency and accuracy of the recombination/transformation of P1+2 and P3 were similarly high in comparison with those of P1 and P2, as shown in the earlier section, although P1+3 was a much larger plasmid than P1 alone.
Next, the feasibility of simultaneously constructing several different types of m-CRAs was tested. DH5a E. coli in each of 10 tubes containing the same P2 (pUni/ CMVpr-EGFP) and Cre aliquot was transformed by each of 10 different types of P1+3 plasmid. At 1 day after the growth on LB-tetracycline plates, 3-52 colonies appeared on each of the 10 cm plates, and all colonies were correctly recombined plasmids (Figure 3c) .
Furthermore, we examined whether more different tumor-specific factors including therapeutic genes can be correctly inserted into m-CRAs with the present system. Eight different m-CRAs that contain six tumor-specific factors, that is, (1) human telomerase reverse transcriptase promoter (TERTpr) driving E1A, (2) wt or mt E1A, (3) human E2F promoter (E2Fpr) driving E1B, (4) mt E1B, We further hypothesized that two types of plasmids, P1+3 and P2, might be recombined directly in Creexpressing 293 cells (Figure 4a ). To assess this possibility, P1+3 (pAd.HM4-CEApr-E1A-CMVpr-E1BD55kD) and (pUni/CMVpr-EGFP) and each of 10 different types of P1+3 plasmid, which were preincubated with the Cre aliquot, were transformed and grew with tetracycline. HindIII-digestion analysis was carried out in the same manner as above, and one representative picture per group was shown here. Numbers of colonies per 10 cm plate appeared and the accuracy (the percentage of the correct clones; clones in each group were carefully analyzed with several different types of restriction enzymes although data were not shown here) in each group is shown below the picture (M, marker. Lanes 1-10, each sample; Pr.A, promoter driving wt or mt E1A; Pr.B, promoter driving wt or mt E1B; P3, P3 plasmid; P1+3, P1+3 plasmid). The 1.8 kb band was indicative of the correct clone. (d) Four different CRAs which contain six tumor-specific factors were constructed and the P1+2+3 plasmids were analyzed by HindIII digestion (M, marker. Lane 1, pAd.HM4-TERTpr-E1A-E2Fpr-E1BD55kD/Surv.pr-p53; Lane 2, pAd.HM4-TERTpr-E1AD24-E2Fpr-E1BD55kD/Surv.pr-p53; Lane 3, pAd.HM12-TERTpr-E1A-E2Fpr-E1BD55kD/Surv.pr-tk; each sample; Lane 4, pAd.HM12-TERTpr-E1AD24-E2Fpr-E1BD55kD/Surv.pr-tk; P3, P3 plasmid).
An efficient construction of m-CRAs S Nagano et al P2 (pUni/CMVpr-EGFP) were cotransfected into Creexpressing 293 cells. Some plaques became visible 6 days afterwards, and 10 plaques per 10 cm dish appeared 12 days after cotransfection. One of these 10 plaques showed an EGFP-positive finding under fluorescent microscopy ( Figure 4b ). PCR analysis of the DNA isolated from these plaques verified that only this fluorescence-positive plaque contained a correctly recombined m-CRA with EGFP cDNA (Figure 4c) . Therefore, using a marker gene such as EGFP, the correct m-CRA derived from P1+2+3 plasmid can be easily isolated from the m-CRA derived from P1+3 plasmid.
Discussion
The large size of the adenoviral DNA (36 kB) hampered the feasible modification of the Ad vector, due to limited numbers of available unique restriction enzyme recognition sites. For constructing the E1-deleted Ad, a twoplasmid system, that is, separate construction of the therapeutic gene and adenoviral backbone in two plasmids, was recently utilized. 23 However, when constructing CRAs, a modification of the E1 region is additionally necessary; currently, there is no standardized method to construct diverse types of m-CRAs in large numbers. Owing to this deficiency, many molecular biologists or gene therapy researchers, who are not CRA specialists, may not be able to efficiently construct CRAs, whereas they can feasibly construct E1-deleted Ad using commercially available kits. Detailed protocols, incorporating the careful consideration of available restriction enzyme sites, should be formulated each time a new CRA is constructed or any time a currently available CRA is modified. The procedures used currently may vary in the details of constructing different m-CRAs, and additional modifications of their own protocols in individual laboratories may be necessary depending on individual CRAs. Thus, even though it may be possible to construct an m-CRA, the present methods are not yet standardized and are deficient in their potential to be widely utilized by a large number of researchers.
In this respect, the notable feature of our system is that it allows the independent and unrestricted construction of individual elements of viral replication, therapeutic genes, and adenoviral backbones in three plasmids, and subsequently permits the accurate fusion of these plasmids within the same protocol into a single m-CRA plasmid without regular ligation procedures. This feature enables a normally trained molecular biologist to feasibly construct m-CRAs, and to construct and/or modify diverse m-CRAs in large numbers. To this end, we introduced Cre/lox recombination and I-CeuI/PI-SceIbased ligation for combining the three plasmids, and different types of antibiotic resistance genes and ori for specifically selecting only the correctly combined clones, into this system. In this context, the factors needed for this system to function at its maximum efficiency were the use of both an optimized concentration of tetracycline, and high-activity Cre. Due to the fact that there have been no reports of tetracycline selection together with the Cre/lox recombination in E. coli, and because we obtained a lower transformation efficiency with tetracycline than with kanamycin or ampicilin, we initially determined the optimal concentration of tetracycline for this system. Unexpectedly, the optimal concentration of tetracycline was 5 mg/ml in the LB plate, which is lower than that described in textbooks (12 mg/ml), 27 and the effective range was narrow (data not shown). Higher Cre activity is also essential, especially due to the use of tetracycline selection; the use of lower Cre activity did not result in the appearance of the correct clone. We established a feasible and inexpensive way to obtain aliquots containing highly active Cre. With these conditions, sufficient numbers of clones always appeared, and all of them contained the correct recombined plasmid. The distinct advantage of the present method is 100% accuracy of correct clones among all of the transformed clones in E. coli; this feature, together with the use of miniprep DNA throughout the procedure, allowed us to handle multiple diverse samples at one time, and we in fact simultaneously constructed diverse types of mCRAs in this study. The remnant components of tet r , R6Kg ori, and a single lox sequence in m-CRAs, which are indispensable to achieve 100% accuracy of correct clones, . PCR analyses were performed using four different primer sets of S-E1A-1/AS-E1A-1, S-E1B-1/AS-E1B-1, S-Fiber/AS-Fiber, and S-EGFP/AS-EGFP to detect E1A, E1B, fiber, and EGFP DNA, respectively. P, positive control plasmid DNA corresponding to each of primer sets. N, nontemplate DNA.
An efficient construction of m-CRAs S Nagano et al are not troublesome, at least for the experimental purpose, probably in general, described herein because neither tet r lacking a proper mammalian promoter or poly A sequence, nor R6Kg ori efficiently function in mammalian cells. In fact, we found that several m-CRAs, including the ones shown in Figure 3c in this study, function well with these components without any harmful effects.
An introduction of a marker gene into a CRA, such as EGFP gene used in the present study, which allows researchers to monitor the spread of a CRA in vitro and in vivo, is quite useful for carefully analyzing the virological features of CRA. It was recently shown that CRA expressing a therapeutic gene may enhance the cytotoxicity and the therapeutic potential in addition to the oncolytic activity of CRAs. 19 In this regard, an advantage of our system is the ability to subsequently insert a therapeutic or marker gene either into an m-CRA plasmid in E. coli or directly into m-CRA in Creexpressing 293 cells. To maximize both protocols, diverse types of P1+3 and P2 may be initially prepared using the regular subcloning procedure, because combining different types of P1+3 and P2 at the later stage can be carried out simultaneously, as shown in the present study. The latter protocol, that is, direct transfection of P1+3 and P2 into Cre-expressing 293 cells, has the advantage of further eliminating one step in E. coli, leading to an increase in the rapidity of the procedure. EGFP or other fluorescent genes alongside the therapeutic gene in P2, which allows direct identification of the correct m-CRA plaque containing therapeutic genes under fluorescent microscopy, may maximize this benefit.
The unrestricted and independent construction of individual elements in the three-plasmid system should not only expedite the process of generating diverse m-CRAs but also make feasible the modification of individual elements in m-CRAs. Several combination patterns of different P1, P2, and P3 vectors allow the generation of diverse types of m-CRAs in large numbers, including those in which some elements were modified with diverse combinations. Lessons from previous gene therapy studies, that is, discrepancies between experimental data and actual clinical outcomes, suggest the necessity of the systematic and extensive examination of the biological and virological characteristics of diverse m-CRAs in practice. In this respect, the ability to efficiently generate large numbers of modified m-CRAs with diverse combinations of gene elements may be the most significant advantage of our system. Particularly, unrestricted selection of the adenoviral backbone may provide two potential advantages. First, any suitable adenoviral backbone, such as fiber-modified Ads to achieve tumor-specific infection, which may be determined by other types of extensive studies, can be directly used in the m-CRA studies; additional steps in constructing new m-CRAs that contain both characteristic elements may be omitted. Second, Ad can package 105% of its genome, and such DNA size limitation may potentially complicate or hamper the modification of pre-constructed m-CRAs. However, the present system allows the change of the P3 backbone plasmid to circumvent this problem; P3 with a longer deletion can be used if additional DNA should be inserted in P1 or P2 to modify pre-established m-CRA. Namely, the threeplasmid system in the present m-CRA construction may maximize the benefit of the in vitro ligation system. 23 For instance, up to 5.4, 5.9 or 8.7 kb of DNA elements can be introduced in P1 and P2 when pAdHM4, pAdHM10, or pAdHM12 is used as P3 vector, respectively, as described previously. 23 In conclusion, the present study reports a novel method for efficiently constructing and/or modifying diverse m-CRAs; this system may be useful for the development of the ideal m-CRA for tumor therapy.
Materials and methods
Cell lines
The human hepatoma cell line, Hep-G2, was obtained from the Cell Resource Center for Biomedical Research at the Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan). Hep-G2 was cultured in Dulbecco's modified Eagle's medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% fetal bovine serum. The Cre-expressing 293 cell line was generated as described elsewhere. 28 
Plasmids
Plasmid P1 was constructed as follows. The E1A coding sequence and pA without the native E1A promoter were obtained by PCR from pXC1 (Microbix, Toronto, Canada) with the primers S-E1A/AS-E1A (Table 1 ). This E1A fragment was digested with SphI and SalI and inserted into SphI/SalI-digested pHM5. 23 The resulting plasmid was designated pDPrE1A. The mt E1B coding sequence (1684-2285), which lacked the E1B55kD coding sequence, native E1B promoter, and pA, was obtained by PCR from pXC1 with the primers S-E1BD55kD/AS-E1BD55kD (Table 1 ) and inserted into pDPrE1A by SalI/BamHI sites, resulting in pDPrE1A-DPrE1BD55kDDpA plasmid. BGHpA obtained by PCR with the primers S-BGHpA/ AS-BGHpA (Table 1 ) from pRc/CMV plasmid (Invitrogen, Carlsbad, CA, USA) was inserted into pDPrE1A-DPrE1BD55kDDpA by BamHI/EcoRI sites, resulting in pDPrE1A-DPrE1BD55kD plasmid. The full length of E1B (1684-4073) was obtained by PCR from pXC1 with the primers S-E1B/AS-E1B (Table 1 ) and inserted into KpnI/EcoRI-digested pDPrE1A-DPrE1BD55kD, resulting in DPrE1A-DPrE1B plasmid. All sequences obtained by PCR were confirmed using an ABI Prism 310 genetic analyzer (Applied Biosystems, Foster City, CA, USA).
E1A sequence without a 24 bp sequence for pRb binding was obtained by site-directed mutagenesis using sequential PCR steps 27 with the primers AS-E1AD24/ S-E1AD24 (Table 1 ). The obtained product was inserted into pDPrE1A-DPrE1B or pDPrE1A-DPrE1BD55kD plasmid by NotI/SalI sites, resulting in pDPrE1AD24-DPrE1B or pDPrE1AD24-DPrE1BD55kD plasmid, respectively.
Plasmid P2 was constructed as follows. kan r was removed from pUni/V5-HisC (Invitrogen) by BglII/SmaI digestion. A blunt-end fragment of tet r obtained from pBR322 (Invitrogen) was inserted into the vector to yield pUni/V5-HisC-tet r . The construction of plasmid P3 was performed as described previously. 23 CEApr 29 and CMVpr were obtained by PCR from AxCEAprTK (Riken gene bank, Tsukuba, Japan) and pRc/CMV with the primer sets of S-CEApr/AS-CEApr and S-CMVpr/AS-CMVpr, respectively ( Table 1) . The fragment containing CEApr or CMVpr was excised by
An efficient construction of m-CRAs S Nagano et al NotI/MluI or SalI/MfeI, respectively, and ligated into similarly digested pDPrE1A-DPrE1BD55kD or pDPrE1 AD24-DPrE1BD55kD, resulting in pCEApr-E1A-CMVprE1BD55kD or pCEApr-E1AD24-CMVpr-E1BD55kD. Human osteocalcin promoter (OCpr, À834 to +34) 30 and Surv.pr (À173 to À19) 31 were obtained by PCR from genomic DNA (details should be described elsewhere). E2Fpr (À218 to +51) 32 and TERTpr (À181 to +78) 33 were kindly provided by H Fine (National Cancer Institute, Bethesda, MD, USA) and S Kyo (Kanazawa University, Kanazawa, Japan), respectively. P1 plasmids pCEApr-E1A-E2Fpr-E1BD55kD, pCEApr-E1AD24-E2Fpr-E1BD 55kD, pE2Fpr-E1A-CMVpr-E1BD55kD, pE2Fpr-E1AD24-CMVpr-E1BD55kD, pOCpr-E1A-CMVpr-E1BD55kD, pOCpr-E1AD24-CMVpr-E1BD55kD, pTERTpr-E1A-CMVprE1BD55kD, pTERTpr-E1AD24-CMVpr-E1BD55kD, pTERT pr-E1A-E2Fpr-E1BD55kD, and pTERTpr-E1AD24-E2Fpr-E1BD55kD were constructed in the same manner as described above. pUni/V5-HisC-tet r was digested with XhoI and blunted, and the blunt-end fragment of CMVpr, which was excised from pCEApr-E1A-CMVpr-E1BD55kD, was inserted to yield pUni/CMVpr. The EGFP coding sequence from pEGFP-C1 (Clontech, Palo Alto, CA, USA) was inserted into pUni/CMVpr to obtain pUni/CMVpr-EGFP. In the same manner, Surv.pr was inserted into pUni/ V5-HisC-tet r , resulting in pUni/Surv.pr. pUni/CMVpr-p53, pUni/CMVpr-tk, pUni/Surv.pr-p53, and pUni/Surv.pr-tk were constructed by insertion of p53 and HSV-tk fragment excised from pCMV-p53 (Clontech) and pAd.RSV-tk (kindly provided by Z Sheng Guo, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA) into pUni/CMVpr or pUni/ Surv.pr.
PCR
The primer sets used in this study are listed in Table 1 . The PCR conditions that were used for the m-CRA construction are described earlier. For verification of the correct m-CRAs, PCR of genomic DNA, which was extracted from viral plaques with proteinase K digestion phenol/chloroform purification and ethanol precipitation, was performed with primer sets, as shown in Table  1 . The amplified DNA was analyzed by electrophoresis on 1% agarose gel.
Preparation of Ads
All Ads were generated and amplified in 293 cells, and purified in CsCl gradients, as described previously. 5, 23 The titer of the Ads (plaque-forming unit/ml) was measured by a plaque assay on 293 cells. 
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